On August 14, the 2019 "Maker China" Beijing SME Innovation and Entrepreneurship Competition and "Maker Beijing 2019" Innovation and Entrepreneurship Competition successfully ended in Beijing. After two months of fierce competition, 30 winners were finally determined. They won the first, second and third prizes of the Enterprise Group and Maker Group respectively. Bai Yi, General Manager of Beijing Dongfang Baitai, attended the meeting and took the stage to receive trophies and bonuses.

On June 12, 2019, in order to implement the deployment of the CPC Central Committee and the State Council on "improving the environment for entrepreneurship and innovation", "giving full play to the role of" Maker China "competition and other brand events, and strengthening follow-up support for outstanding innovation and entrepreneurship projects emerging from various events". In order to further stimulate the vitality of "mass entrepreneurship and innovation" and guide and enhance market confidence, the Ministry of Industry and Information Technology and the Ministry of Finance jointly held the 2019 "Maker China" SME Innovation and Entrepreneurship Competition. The purpose of this event is to stimulate innovation potential, gather entrepreneurial resources and create an atmosphere of "mass entrepreneurship and innovation". We will work together to create a platform for SMEs and makers to provide exchanges and exhibitions, industry finance docking, and project incubation, explore and cultivate a number of excellent projects and teams, promote new products, new technologies, new models, and new business formats, and improve the professionalism and level of SMEs. We will promote the transformation, upgrading and growth of small and medium-sized enterprises to become specialized, special and new "small giants", promote the coordinated innovation and development of large, small and medium-sized enterprises, and help build a manufacturing power and a network power.

Qin Zhihui, Deputy Director of the SME Bureau of the Ministry of Industry and Information Technology, affirmed the achievements of this competition in his speech. He said that the Beijing competition area is the most important regional competition of the "Maker China" competition. Great achievements have been made over the years, and a large number of high growth SMEs with core innovation capabilities have emerged. Wang Ying, Deputy Director of the Municipal Finance Bureau, said in his speech that the municipal finance department would constantly innovate the way of using financial funds. We will continue to optimize the business environment for SMEs, give further play to the guiding role of financial funds, and encourage diversified market service institutions to provide better services for SMEs. Comrade Wang Gang, Director of the Municipal Bureau of Economy and Information Technology, summarized the competition. He said that we will take this competition as an opportunity to accelerate the collection of high-quality service resources and serve a number of excellent entrepreneurial enterprises and makers' teams. We will further stimulate the innovative potential and creativity of small and medium-sized enterprises and promote high-quality economic development in the capital.

There are 1670 registered projects in this competition. It covers ten high-tech industries, cultural and creative industries, new convenient service industries and other fields. It lasted more than 60 days. At 109 competition points in 14 competition areas, including Yizhuang, Haidian and Changping, Beijing Dongfang Baitai finally achieved excellent results through four links of pre competition project solicitation, preliminary competition, semi-final competition and final competition.

JY09 is a long-acting GLP-1 analog drug. JY09 is one of the new drugs independently developed by Beijing Dongfang Baitai. It has won the "triple" project of the national major new drug discovery project and the "priority review" project recommended by the National Health and Family Planning Commission. It has domestic and foreign invention patents in China, the United States, the European Union, Eurasia, Japan, South Korea, India, etc. At present, Phase I clinical study has been completed. Phase II clinic is being carried out. The research shows that JY09 has a longer half-life than similar products. It is expected that the drug can be administered once every 7-14 days. It is a world leading level with good safety and tolerance. JY09 is different from traditional medicine. It can steadily control the blood sugar level of patients, reduce the risk of hypoglycemia, and improve the safety of patients' medication. The product can promote the secretion of insulin. It has the function of repairing islets of langerhans and is suitable for the treatment of type 2 diabetes patients.

Dongfang Baitai was founded in 2011. Located in Yizhuang Development Zone, it covers an area of about 60000 square meters. It is a high-tech enterprise engaged in the R&D and production of innovative antibody drugs, focusing on new products of major disease treatment and preventive biological medicine.

At present, biotechnology drugs are the hotspot and key field of global drug research and development. Over the years, Dongfang Baitai has successively set up projects to research and develop more than 20 biotechnology drugs. The company has built an industrial technology platform with world advanced level, focusing on original antibody drugs and new therapeutic vaccines, and running through the whole process of R&D and production. The product indications cover many high incidence diseases such as malignant tumor, diabetes, rheumatoid arthritis, psoriasis, hyperlipidemia, etc. The product category includes all human monoclonal antibody, humanized monoclonal antibody, bispecific antibody, antibody fusion protein, antibody conjugated drug, therapeutic vaccine, autoimmunity, ophthalmology and other disease fields. At present, the company has 6 drugs under clinical research.

The company has an antibody R&D and production base of 40000 square meters. Three production lines of 200L pilot cell culture and fermentation system, one production line of 3 * 3000L mammalian cell mass batch culture and one production line of bacteria/yeast and other antibody research and development industrial facilities are under construction. It has built a variety of world advanced technological platforms for innovative antibody R&D and production.

With the purpose of "gathering bio pharmaceutical power and creating a healthy life for human beings", Dongfang Baitai is continuously committed to providing high-quality and efficient antibody drugs for patients, improving the quality of life of patients and protecting healthy life. We are making unremitting efforts to establish a biomedical innovative enterprise that has attracted worldwide attention!